Aquestive Therapeutics, Inc. (AQST)
4.80
+0.14
(+3.00%)
USD |
NASDAQ |
Aug 24, 16:00
4.71
-0.09
(-1.88%)
After-Hours: 20:00
Aquestive Therapeutics Enterprise Value : 653.05M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 653.05M |
| August 21, 2026 | 635.48M |
| August 20, 2026 | 614.77M |
| August 19, 2026 | 626.69M |
| August 18, 2026 | 592.81M |
| August 17, 2026 | 589.04M |
| August 14, 2026 | 584.02M |
| August 13, 2026 | 584.02M |
| August 12, 2026 | 581.51M |
| August 11, 2026 | 604.10M |
| August 10, 2026 | 589.04M |
| August 07, 2026 | 545.11M |
| August 06, 2026 | 542.60M |
| August 05, 2026 | 521.89M |
| August 04, 2026 | 520.01M |
| August 03, 2026 | 526.28M |
| July 31, 2026 | 514.36M |
| July 30, 2026 | 517.50M |
| July 29, 2026 | 502.44M |
| July 28, 2026 | 522.52M |
| July 27, 2026 | 518.75M |
| July 24, 2026 | 512.48M |
| July 23, 2026 | 523.77M |
| July 22, 2026 | 545.11M |
| July 21, 2026 | 557.66M |
| Date | Value |
|---|---|
| July 20, 2026 | 545.74M |
| July 17, 2026 | 567.70M |
| July 16, 2026 | 545.11M |
| July 15, 2026 | 546.37M |
| July 14, 2026 | 557.66M |
| July 13, 2026 | 560.17M |
| July 10, 2026 | 567.70M |
| July 09, 2026 | 582.76M |
| July 08, 2026 | 591.55M |
| July 07, 2026 | 594.06M |
| July 06, 2026 | 582.76M |
| July 02, 2026 | 575.23M |
| July 01, 2026 | 582.76M |
| June 30, 2026 | 572.72M |
| June 29, 2026 | 539.87M |
| June 26, 2026 | 568.45M |
| June 25, 2026 | 577.77M |
| June 24, 2026 | 643.02M |
| June 23, 2026 | 648.00M |
| June 22, 2026 | 609.47M |
| June 18, 2026 | 608.22M |
| June 17, 2026 | 573.42M |
| June 16, 2026 | 552.30M |
| June 15, 2026 | 547.32M |
| June 12, 2026 | 541.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| LENZ Therapeutics, Inc. | -75.23M |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
| Veru, Inc. | 21.05M |
| Johnson & Johnson | 685.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.86M |
| Revenue (Quarterly) | 13.82M |
| Total Expenses (Quarterly) | 36.68M |
| EPS Diluted (Quarterly) | -0.1829 |
| Gross Profit Margin (Quarterly) | 70.93% |
| Profit Margin (Quarterly) | -165.5% |
| Earnings Yield | -13.53% |
| Normalized Earnings Yield | -12.17 |